|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.68 USD | +1.47% |
|
+7.05% | +13.47% |
| 01-13 | Alkermes plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM | |
| 01-12 | Avadel Pharmaceuticals Shareholders Approve Buyout by Alkermes | MT |
| Capitalization | 5.15B 4.44B 4.14B 3.85B 7.17B 468B 7.72B 47.59B 18.76B 223B 19.33B 18.93B 815B | P/E ratio 2025 * |
21.2x | P/E ratio 2026 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise value | 4.05B 3.49B 3.25B 3.03B 5.64B 368B 6.07B 37.42B 14.75B 175B 15.2B 14.89B 641B | EV / Sales 2025 * |
2.75x | EV / Sales 2026 * | 2.9x |
| Free-Float |
90.15% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Alkermes plc
| 1 day | +1.47% | ||
| 1 week | +7.05% | ||
| Current month | +13.47% | ||
| 1 month | +13.15% | ||
| 3 months | +3.08% | ||
| 6 months | +8.73% | ||
| Current year | +13.47% |
| 1 week | 28.93 |  | 31.96 |
| 1 month | 27.5 | | 31.96 |
| Current year | 27.5 | | 31.96 |
| 1 year | 25.16 | | 36.45 |
| 3 years | 22.01 | | 36.45 |
| 5 years | 18.02 | | 36.45 |
| 10 years | 11.98 | | 71.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 64 | 1991-01-31 |
Joshua Reed
DFI | Director of Finance/CFO | 53 | 2025-09-14 |
Thomas Harvey
CTO | Chief Tech/Sci/R&D Officer | - | 2004-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Pops
CHM | Chairman | 64 | 2011-08-31 |
Nancy Snyderman
BRD | Director/Board Member | 74 | 2016-05-25 |
Shane Cooke
BRD | Director/Board Member | 63 | 2018-03-29 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -4.17% | 15.32% | 303 M€ | |
| 0.00% | 2.65% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.49% | +7.05% | +6.72% | +11.25% | 5.15B | |
| -0.89% | +1.01% | +2.08% | +11.35% | 49.36B | |
| -0.16% | -0.71% | +21.77% | +8.64% | 41.09B | |
| -0.10% | +0.07% | +64.67% | +26.32% | 37.43B | |
| -0.71% | -1.88% | +20.29% | +35.05% | 31.37B | |
| -2.40% | +1.95% | +203.13% | +341.75% | 23.83B | |
| -3.66% | -36.91% | +22,683.91% | +3,793.01% | 14.86B | |
| +0.29% | +4.28% | +84.22% | +171.41% | 17.41B | |
| -0.47% | +4.10% | +54.27% | +11.12% | 14.86B | |
| +2.15% | +2.86% | -7.85% | -17.24% | 13.94B | |
| Average | -0.44% | +0.27% | +2,313.32% | +439.26% | 24.93B | |
| Weighted average by Cap. | -0.63% | +1.10% | +1,396.89% | +282.73% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.48B 1.27B 1.18B 1.1B 2.05B 134B 2.21B 13.63B 5.37B 63.89B 5.54B 5.42B 233B | 1.79B 1.55B 1.44B 1.34B 2.5B 163B 2.69B 16.57B 6.53B 77.67B 6.73B 6.59B 284B |
| Net income | 247M 213M 198M 185M 344M 22.43B 370M 2.28B 900M 10.7B 927M 908M 39.07B | 269M 232M 216M 201M 374M 24.42B 403M 2.48B 980M 11.65B 1.01B 989M 42.54B |
| Net Debt | -1.1B -950M -884M -823M -1.53B -99.98B -1.65B -10.17B -4.01B -47.69B -4.13B -4.05B -174B | 45.91M 39.58M 36.85M 34.3M 63.87M 4.17B 68.72M 424M 167M 1.99B 172M 169M 7.26B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 31.74 $ | +1.68% | 913,863 |
| 26-01-15 | 31.22 $ | +1.96% | 2,897,250 |
| 26-01-14 | 30.62 $ | +5.04% | 1,860,765 |
| 26-01-13 | 29.15 $ | -1.59% | 2,082,291 |
| 26-01-12 | 29.62 $ | -0.13% | 1,675,542 |
Delayed Quote Nasdaq, January 16, 2026 at 01:59 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALKS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition